Search Results
Dec 30, 2025, 18:13 ET Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
placebo-controlled clinical trials, somnolence (6%, 12%) and fatigue (6%, 8%) were adverse reactions reported in subjects who took a single dose of 85 mg or 170 mg NEREUS™, respectively. NEREUS™ may impair the mental and/or physical abilities required for driving a motor vehicle or operating heavy machinery.
More news about: Vanda Pharmaceuticals Inc.
Dec 26, 2025, 15:46 ET IDSS 2025: 90% das melhores operadoras do Brasil são Unimed
(SP), Unimed Ribeirão Preto (SP), Unimed do Estado de Santa Catarina – Federação Estadual das Cooperativas Médicas (SC), Unimed Uberlândia (MG), Unimed Belo Horizonte (MG) e Unimed Porto Alegre (RS).Além das cooperativas médicas, a Seguros Unimed também se destacou no IDSS 2025, ao alcançar nota máxima
More news about: Unimed
Dec 26, 2025, 08:19 ET Baker Health Launches MELT, a Personalized, Capsule-Based Weight Loss Program Designed as a Non-Injection Alternative to GLP-1s
and one in the evening, designed to support the body's natural metabolic rhythms. The morning capsule combines phentermine, titrated from 5 mg to 10 mg to 15 mg over three months, with bupropion, naltrexone, berberine, and a probiotic to support appetite control and metabolic function during the day.
More news about: Baker Health
Dec 24, 2025, 08:04 ET Foresee Pharmaceuticals announces the Casppian Phase 3 Study Meets Primary Efficacy Endpoint, Demonstrating Robust LH Suppression with 6-Month Dosing Interval of leuprolide mesylate
affected children. The current standard of care involves treatment with GnRH agonists to halt pubertal progression.About FP-001 42 mgFP-001 42 mg is an investigational, sustained-release formulation of a GnRH agonist being developed for the treatment of CPP. It is designed to provide
More news about: Foresee Pharmaceuticals Co., Ltd.
Dec 24, 2025, 08:00 ET Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy
NT-proBNP, reduced left ventricular filling pressures, and improved relaxation metrics.In addition to the 50 mg and 100 mg fixed doses previously reported, the Company evaluated a lower 25 mg fixed dose in 4 oHCM and 10 nHCM participants in CIRRUS-HCM Parts B and C, respectively. In these cohorts, evidence
More news about: Edgewise Therapeutics
Dec 23, 2025, 08:43 ET Pusan National University Researchers Discover Faster, Smarter Heat Treatment for Lightweight Magnesium Metals
properties.ReferenceTitle of original paper: Validating the athermal contribution of electropulsing treatment utilizing T-type Mg specimenJournal: Journal of Magnesium and AlloysDOI:
More news about: Pusan National University
Dec 23, 2025, 00:03 ET Fapon Biopharma Publishes Pioneering Research in Cell Reports Medicine on FP008, an anti-PD 1 X IL-10M Fusion Protein for Cancer Immunotherapy
systemic exposure.In comprehensive GLP toxicology studies in cynomolgus monkeys, FP008 exhibited a favorable safety profile at doses up to 10 mg/kg, with no significant hematological adverse events observed. The data supported that this approach has the potential to overcome prior clinical limitations
More news about: Fapon Biopharma
Dec 22, 2025, 18:03 ET FDA approves Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults
environment.8,9What is Wegovy®?Wegovy® (semaglutide) injection 1.7 mg or 2.4 mg and Wegovy® (semaglutide) tablets 25 mg are prescription medicines used with a reduced calorie diet and increased physical activity to:reduce
More news about: NOVO NORDISK INC.
Dec 22, 2025, 09:12 ET Tanabe Pharma America Announces Transfer of RADICAVA® Business to Shionogi
treatment cycle. For subsequent treatment cycles, RADICAVA ORS is taken for 10 days within a 14-day period followed by a 14-day drug-free period. Each 105 mg (5mL) dose of RADICAVA ORS should be taken in the morning after overnight fasting. Patients should not eat or drink (except water) within one hour after
More news about: Tanabe Pharma America
Dec 22, 2025, 07:00 ET U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
(HR) for the JASCAYD 18 mg or 9 mg groups compared to placebo for the key secondary composite endpoint (JASCAYD 18 mg or 9 mg groups, respectively, compared to placebo: HR 0.77 [95% CI: 0.59, 1.01] and HR 0.88 [95% CI: 0.68, 1.14]).5 Further results for JASCAYD 18 mg in respect to the key secondary
More news about: Boehringer Ingelheim
Dec 22, 2025, 01:06 ET セピエンス™（セピアプテリン）、フェニルケトン尿症（PKU）の治療薬として製造販売承認取得
東京, Dec. 22, 2025 /PRNewswire/ -- PTCセラピューティクス株式会社は、本日、厚生労働省（MHLW）により、セピエンス™顆粒分包250mg、同1000mg（セピアプテリン）がフェニルケトン尿症（PKU）の治療薬として承認されたことを発表しました。幅広い年齢層および病型のPKU患者様が治療の対象となります。
More news about: PTC Therapeutics, Inc.
Dec 19, 2025, 07:55 ET Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
standard approaches."The dose-escalation phase features high entry doses supported by strong tolerability in non-human primates at up to 50 mg/kg, with initial clinical data expected in mid-2026. Sutro's proprietary cell-free platform produces STRO-004 with site-specific β-glucuronidase
More news about: Equity Insider
Dec 19, 2025, 07:45 ET BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
approval to market a generic version of Galafold 123 mg capsules prior to expiration of the certain Amicus patents. In connection with the resolution of the patent litigation, Amicus entered into License Agreements with Aurobindo and Lupin for Galafold 123 mg capsules. Pursuant to the terms of the agreements,
More news about: BioMarin Pharmaceutical Inc.
Dec 19, 2025, 07:44 ET Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
transplant-eligible and transplant-ineligible patients."The broad clinical development program includes ongoing Phase 2 expansion at the recommended 200mg dose and the LINKER-MM6 trial evaluating combination therapy in transplant-ineligible newly diagnosed patients. Regeneron will host a virtual
More news about: USA News Group
Dec 18, 2025, 14:26 ET ANVISA aprova Metalyse® 25mg da Boehringer Ingelheim para o tratamento de AVC isquêmico agudo
SÃO PAULO, 18 de dezembro de 2025 /PRNewswire/ -- A Boehringer Ingelheim anuncia a aprovação de Metalyse® 25mg (tenecteplase) pela Anvisa em 8 de dezembro para o tratamento de pacientes com acidente vascular cerebral isquêmico agudo (AVCi)1. O AVC é
More news about: Boehringer Ingelheim
Dec 18, 2025, 11:13 ET Sports Research® Announces Unprecedented Expansion at Costco, Marking a Transformational Moment for a Brand on the Rise in Retail Wellness
ingredients; Costco-first launchSUPERBA2® Krill Oil 1000 mg (90 softgels): MSC-certified sustainably sourced krill providing phospholipid-bound omega-3s with choline and astaxanthinCoQ10 200 mg (150 veggie softgels): Vegan Certified, seed-oil-free formula with enhanced
More news about: Sports Research
Dec 18, 2025, 09:00 ET American Life Expands Product Availability to New Hampshire
processing timelines.MaxGrowth is issued by American Life & Security Corp., 2900 S. 70th St., STE 400, Lincoln, NE 68506 (FIA5 11/2023; FIALR-MG 01/24, ICC24-FIANHR 001 01/24, FIAPB 001/24) or state variations. Product Features, limitations and availability vary; see the MaxGrowth FIA Disclosure
More news about: American Life
Dec 18, 2025, 08:00 ET Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
CagriSema 2.4 mg/2.4 mg is an investigational fixed-dose injectable medicine that combines the novel amylin analogue, cagrilintide, with semaglutide to target complementary obesity-related pathways1,2In the REDEFINE 1 phase 3 trial, adults with obesity,
More news about: NOVO NORDISK INC.
Dec 18, 2025, 08:00 ET Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
CagriSema 2.4 mg/2.4 mg is an investigational fixed-dose injectable medicine that combines the novel amylin analogue, cagrilintide, with semaglutide to target complementary obesity-related pathways1,2In the REDEFINE 1 phase 3 trial, adults with obesity,
More news about: NOVO NORDISK INC.
Dec 18, 2025, 06:45 ET Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
in a 1:1 ratio to receive maximum tolerated dose of Zepbound (10 mg or 15 mg) or Wegovy (1.7 mg or 2.4 mg). With Zepbound, 89.3% received at least one dose of the 15 mg dose and with Wegovy 92.8% received at least one dose of the 2.4 mg dose. The primary objective of the study was to demonstrate Zepbound's
More news about: Eli Lilly and Company
Dec 17, 2025, 19:00 ET Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature
HbA1c from baseline were -1.61% for mazdutide 4 mg, -1.66% for mazdutide 6 mg, and -1.36% for dulaglutide 1.5 mg at Week 28, respectively. The proportion of participants achieving HbA1c <7% were 67.7% and 70.4% with mazdutide 4 mg and 6 mg, respectively, versus 61.6%. These findings were
More news about: Innovent Biologics
Dec 17, 2025, 17:00 ET PLAYBOY ENERGY DRINK TO FUEL PERFORMANCE, PLEASURE & PASSION FOR GEN Z
that stands apart from what their parents drink, while embracing all consumers with its flavors and function.Playboy Energy Drink delivers 200mg of caffeine, Vitamin B-Complex and L-Carnitine with just 30 calories for improved performance, enhanced mental and physical wellbeing and uncompromising
More news about: Fire Brands
Dec 17, 2025, 16:38 ET Clywedog Therapeutics Announces Activation of All Centers and Patient Dosing in Multicenter, International Phase 1b Clinical Study of Balomenib in Type 2 Diabetes
pharmacodynamics, along with favorable safety and tolerability, in the completed Phase 1 single- and multiple-ascending dose studies, with dosing evaluated up to 600 mg twice daily, the highest dose tested. Targeting menin-dependent biology offers a differentiated and potentially disease-modifying approach, and this
More news about: Clywedog Therapeutics, Inc.
Dec 17, 2025, 16:01 ET Insmed Provides Clinical and Business Update
polyps (CRSsNP) did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg treatment arms. Brensocatib was well tolerated, with no new safety signals identified, including in the 40 mg arm, which is the highest dose Insmed has studied to date. Insmed has discontinued its development
More news about: Insmed Incorporated
Dec 17, 2025, 11:30 ET New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations
Both monthly maintenance doses (100 mg and 300 mg) improved opioid abstinence and were well-tolerated with no new safety signals identified.Post-hoc analyses indicated the 300-mg monthly maintenance dose performed significantly better than the 100-mg monthly dose in participants reporting
More news about: Indivior PLC